[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634690":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":10,"locations":34,"responsibleParty":53,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Amsterdam UMC, location VUmc","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Transgender males",null,"Individuals clinically scheduled to start GAHT with testosterone therapy",[13,14,15],"Diagnostic Test: P-aminohippurate clearance study","Diagnostic Test: Iohexol infusion","Diagnostic Test: Hyperinsulinemic clamp",{"label":17,"type":10,"description":18,"interventionNames":19},"Transgender women","Individuals clinically scheduled to start GAHT with estradiol and anti-androgen therapy",[13,14,15],[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","P-aminohippurate clearance study","To measure effective renal plasma flow (ERPF), small doses of a substance called p-aminohippurate will be used",[9,17],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Iohexol infusion","To measure glomerular filtration rate (GFR) iohexol clearance will be performed",[9,17],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Hyperinsulinemic clamp","Glucose\u002Finsulin infusion to measure insulin sensitivity",[9,17],[35],{"facility":36,"status":10,"city":37,"state":38,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Amsterdam UMC, location VU medical centre, internal medicine","Amsterdam","North Holland","Netherlands","NL",{"type":42,"coordinates":43},"Point",[44,45],4.88969,52.37403,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":51,"phoneExt":10,"email":52},"A. S. Olde Monnikhof, Drs.","CONTACT","+3120 444 4444","a.oldemonnikhof@amsterdamumc.nl",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Daniel van Raalte","Prof. Dr.",[58],{"name":59,"class":6},"Dutch Kidney Foundation","100634690","transgender-analysis-of-nephrological-studies-focused-on-renal-metrics-100634690",false,"NCT07542964","Transgender Analysis of Nephrological Studies Focused on Renal Metrics","TRANSFORM","Inclusion Criteria:\n\n* Diagnosed with gender dysphoria according to DSM-V\n* Expected to start gender-affirming hormone treatment in the upcoming month\n\nExclusion Criteria:\n\n* Current or prior use of gender-affirming hormone therapy\n* Participation in other studies\n* Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)\n* Known kidney disease (eGFR \\\u003C 60 ml\u002Fmin; UACR \\> 2.5 mg\u002Fmmol)\n* Diabetes mellitus\n* A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease, or a previously undiagnosed arrhythmia)\n* Known iodine-related allergies\n* Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)\n* Pregnancy\n* Claustrophobia","ALL","18 Years","40 Years",{"count":71,"type":72},60,"ESTIMATED","OBSERVATIONAL","This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.",[76,77,78],"Kidney Disease","Kidney Injury","Transgender Individuals",[80,81,82,83,84],"Transgender individuals","Kidney disease","Kidney injury","Gender affirming hormone treatment","Sex hormones","NOT_YET_RECRUITING","2026-04-17",{"date":88,"type":89},"2026-04-21","ACTUAL",{"date":91,"type":72},"2026-09",{"date":93,"type":72},"2028-09",{"name":5,"class":6},1]